Phase 3 Psoriatic Arthritis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 18 years of age or older at the time of signing the consent form (in South Korea, this requirement is 19 years or older)
- People who completed the full 52-week treatment period in one of the two related earlier studies (TAK-279-PsA-3001 or TAK-279-PsA-3002), regardless of which treatment they were assigned to, and who were not required to permanently stop their study treatment during that time
- People whose doctor believes would benefit from continuing, or starting for the first time, treatment with the study drug zasocitinib
Who may not be able to join:
- People whose doctor considers they have not benefited from the study drug, based on their symptoms not improving or getting worse during the earlier study
- People who were required to permanently stop their study treatment during the earlier study, based on the stopping rules defined in those studies
- People who have developed certain other medical conditions since joining the earlier study that could affect how results are assessed, including (but not limited to) rheumatoid arthritis, certain types of spinal inflammatory disease, lupus, Lyme disease, gout, or fibromyalgia (confirm with trial site)
- People who have developed a type of skin condition that, in the doctor's opinion, could interfere with study assessments — such as certain forms of psoriasis other than the common plaque type (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Study Director, Takeda
Phone: +1-877-825-3327
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs); Number of Participants With Adverse Events of Special Interest (AESI); Number of Participants With Clinically Significant Changes in Vital Sign Values; Number of Participants With Clinically Significant Changes in Clinical Laboratory Values
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.